Actinium pharmaceuticals, inc. (ATNM)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11
Cash Flows from Operating Activities:
Net loss

-4,602

-6,599

-5,026

-5,670

-6,319

-6,148

-4,862

-6,323

-5,163

-6,322

-7,053

-8,061

-6,695

-6,598

-6,624

-4,403

-6,540

-3,946

-7,463

-3,074

-5,426

-6,077

3,515

-16,699

-5,879

-1,420

-2,784

-689

-2,877

-3,012

-1,562

-908

-4

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

311

390

276

316

386

405

425

579

639

681

1,141

1,030

1,219

1,015

1,077

984

753

1,133

2,266

2,908

1,058

2,080

1,390

1,750

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

104

106

105

103

12

13

12

11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

94

1,911

72

40

199

-

Depreciation expense

-

-

-

-

-

-

-

-

-

-

-

-

-

20

19

18

-

16

16

10

-

-

-

-

1

0

0

0

0

0

0

0

-

Loss on disposition of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-4

-

-

-

-

-

Depreciation expense

-

-

-

-

-

-

-

-

9

11

14

20

-

-

-

-

-

-

-

-

-

14

8

1

-

-

-

-

-

-

-

-

-

Loss on disposition of equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

97

226

229

221

-

Amortization of deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

32

73

72

72

-

Gain on extinguishment of liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

Gain on change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

38

372

149

-255

131

502

295

1,601

-1,620

694

-57

4,796

1,447

967

7,939

-12,561

-4,395

189

-1,307

1,334

973

-294

-402

409

-

Changes in operating assets and liabilities:
Decrease in:
R&D reimbursable receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0

-50

-

Prepaid expenses and other current assets

173

-146

36

-316

28

-258

-217

348

-233

-336

-21

-805

277

635

-14

133

380

-99

-376

-65

-294

63

-25

449

7

-29

-135

50

32

-22

-3

11

-

Increase (decrease) in:
Accounts payable and accrued expenses

-575

430

-617

-493

1,661

-1,143

-4

620

1,150

-154

-1,164

573

1,623

1,191

-473

378

585

-122

-236

-1,019

522

685

430

236

66

-481

333

-437

160

437

-100

-163

-

Operating lease liabilities

-75

-72

-64

-62

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses-related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-13

13

-282

93

-63

88

0

108

-294

344

0

0

29

2

0

0

-

Increase in Legal fees payable (Statement Of Cash Flows)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Increase in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

Increase in accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

Rounding error (Statement Of Cash Flows)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Used In Operating Activities

-5,010

-5,598

-5,362

-5,489

-4,286

-6,614

-4,210

-5,459

-3,168

-5,869

-7,139

-5,374

-4,240

-5,570

-6,221

-4,756

-3,964

-3,499

-5,267

-5,813

-5,047

-4,239

-2,571

-2,490

-1,344

-1,620

-1,015

-2,312

-1,417

-1,933

-914

-947

-4

Cash Flows from Investing Activities:
Payment of security deposit

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

49

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment made for patent rights

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Purchase of property and equipment

4

0

8

51

10

58

19

6

1

6

8

8

17

1

13

27

20

25

0

0

0

22

126

1

8

6

0

1

0

0

0

1

-

Decrease of restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets transferred

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash Used In Investing Activities

-4

0

-8

-51

-10

-58

-19

-6

-1

-6

-8

-8

-17

-1

-13

-77

-20

-25

-0

0

-35

-22

-126

-1

-8

-6

0

-1

-0

-0

0

-1

0

Cash Flows from Financing Activities:
Payments on note payable

25

75

74

73

-

-

-

-

-

-

-

-

0

89

88

87

0

92

97

93

4

54

39

63

0

36

37

65

0

0

0

0

-

Payments on finance leases

18

18

17

17

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales of shares of common stock and warrants, net of offering costs

-

-

-

-

3,165

0

-1,059

14,870

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sale of common stock, net of offering costs

-

-

-

380

-

-

-

-

27

14,962

1,907

1,917

9,250

714

4,572

1,485

4,812

2,350

11,990

18,484

0

1,106

11,457

2,871

-

-

-

-

-

-

-

-

0

Proceeds from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Proceeds from exercise of options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

275

-5

5

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

0

0

0

1,503

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43

14

78

23

-

-

-

0

-

-

-

-

-

Borrowings on convertible debt, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Sales of stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

4,469

0

-0

660

-

Related party notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4

Net Cash Provided By Financing Activities

-44

350

15,015

1,792

3,165

3

-1,058

14,870

27

14,962

1,907

1,917

9,250

643

4,483

1,397

4,866

2,335

11,935

18,391

39

1,341

11,490

2,837

2,896

-33

3,425

-65

4,469

0

-0

660

4

Net change in cash, cash equivalents and restricted cash

-5,058

-5,248

9,644

-3,748

-1,131

-6,668

-5,289

9,403

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

9,085

-5,240

-3,466

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,927

-1,751

-3,436

881

-1,190

6,667

12,578

-5,043

-2,920

8,793

344

1,543

-1,660

2,410

-2,378

3,052

-1,933

-914

-288

0

Supplemental disclosures of cash flow information:
Cash paid for interest

21

0

1

2

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

2

-

0

1

5

0

0

0

0

0

0

0

0

0

0

0

0

-

Cash paid for taxes

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

Supplemental disclosure of non-cash investing and financing activities:
Stock issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

1,115

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Subscription receivable received subsequent to balance sheet date

-

-

-

-

-

-

-

56

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued with stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,738

0

0

0

0

-

-

-

-

-

-

-

-

-

Transfer from derivative liability classification to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

17

0

0

0

48

-

-

-

-

-

-

-

-

-

-

-

-

-

Beneficial conversion feature discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Insurance financed through premium finance agreements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Transfer warrant derivatives from liability to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,113

-109

139

-

-

-

-

-

-

-

-

-

Transfer warrant derivatives from liability to equity classification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,231

0

0

0

-

Fair value of warrants issued with debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

-

Fair value of warrants issued with stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

3,075

0

0

318

-

Fair value of warrants issued to the placement agent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

499

0

0

159

-

Conversion of notes payable and accrued interest to stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

590

0

981

0

0

0

-